RXRX vs VERA Stock Comparison
Compare RXRX and VERA across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between RXRX and VERA?
VERA leads the current stock comparison as Vera Therapeutics, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Recursion Pharmaceuticals, Inc. vs Vera Therapeutics, Inc.
VERA leads
VERA leads by 4 AIQ points, primarily on Momentum, having only recently taken the lead back from RXRX.
Fragile: 2 of 5 evidence groups support VERA, the lead recently changed hands, and its current signal state is conflicted.
Recursion Pharmaceuticals, Inc.
Vera Therapeutics, Inc.
The Algovestiq AIQ Score currently favors VERA over RXRX, 41 versus 37 as of Sep 11, 2026. VERA's advantage is driven primarily by stronger momentum. VERA also shows the stronger technical structure relative to its 50-day moving average. 2 of 5 covered evidence groups favor VERA today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 4 points. VERA lead: Reversed — RXRX led by 7 AIQ points 30 sessions ago; VERA now leads by 4.
Compare Recursion Pharmaceuticals, Inc. and Vera Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare RXRX and VERA against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum38 vs 49VERA +11
- Quality29 vs 27Even
- Risk Resilience58 vs 56Even
2 of 5 evidence groups favor VERA. VERA’s edge is concentrated in momentum.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum +2
No new signals fired.
Largest factor move: Momentum +2
New signals
- Bollinger Band Squeeze — neutral, volatility, short horizon
VERA's lead widened by 1 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — RXRX and VERA both carry a full feed there.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
VERAVERA on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
VERAVERA on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
VERAVERA on the Momentum factor, by 11 points.
Lower downside
VERAVERA carries the lower 1-month annualized volatility.
Analyst upside
VERAVERA on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | RXRX | VERA | Note |
|---|---|---|---|
| Implied upside to target | +68.8% | +147.5% | VERA has more room |
| Target dispersion | +3.7% | +94.5% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 1 | 8 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
2 of 5 covered evidence groups favor VERA. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | VERA | 37 vs 41 |
| Fundamentals | Even | EPS growth -13.6% vs 10.1%; TTM ROE -50.4% vs -84.1% |
| Valuation | Not covered | Not covered |
| Technicals | Even | Price vs 50-day -3.2% vs -0.9%; vs 200-day -13.1% vs -15% |
| Risk Resilience | Even | Risk Resilience 58 vs 56 |
| Analyst expectations | VERA | Target upside 68.8% vs 147.5% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of RXRX and VERA and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 4 points. (argues the conclusion is provisional)
- Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on VERA.
How the comparison changed
119 daily snapshots · May 4 – Sep 10VERA lead: Reversed — RXRX led by 7 AIQ points 30 sessions ago; VERA now leads by 4.
- Today
- VERA +4
- 37 vs 41
- 7 sessions ago
- VERA +5
- 44 vs 49
- 30 sessions ago
- RXRX +7
- 45 vs 38
- 90 sessions ago
- VERA +6
- 46 vs 52
The lead changed hands 7 times in this window, most recently on Sep 9 when VERA moved ahead of RXRX.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
0 bullish / 3 bearish / 1 neutral
- Death Cross Active — bearish, trend, long horizon (9.97%)
- Downtrend Structure Active — bearish, trend, long horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (6.16%)
1 bullish / 2 bearish / 2 neutral, conflicted
- Death Cross Active — bearish, trend, long horizon (11.76%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- Downtrend Structure Active — bearish, trend, long horizon
VERA leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.27%, AIQ 0 points).
Price and the AIQ Score both moved up over the latest session (price +4.32%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1RXRX closes the Momentum gap — currently 11 points behind, the largest single contributor to VERA's edge.
- 2RXRX's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3VERA's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | RXRX | VERA |
|---|---|---|
| Revenue growth (YoY) | 18.5% | 0% |
| EPS growth (YoY) | -13.6% | 10.1% |
| Gross margin | -46.7% | 0% |
| Operating margin | -9.9% | 0% |
| Return on equity (TTM) | -50.4% | -84.1% |
| Debt to equity | 0.07 | 0.18 |
Performance
VERA leads 4 of 6 windows| Metric | RXRX | VERA |
|---|---|---|
| 1 week (5 sessions) | -6.5% | -5.8% |
| 1 month (20 sessions) | -4% | 12% |
| 3 months (63 sessions) | 3.9% | 6.3% |
| 6 months (126 sessions) | -8.4% | -20.1% |
| Year to date | -22.7% | -33.6% |
| 1 year (252 sessions) | -31.6% | 37.9% |
Technicals
Split| Metric | RXRX | VERA |
|---|---|---|
| RSI (14) | 45.1 | 58.5 |
| ADX (14) | 12.8 | 19 |
| Price vs 50-day | -3.2% | -0.9% |
| Price vs 200-day | -13.1% | -15% |
| Volatility (1M, annualized) | 82.8% | 59.6% |
Risk
Split| Metric | RXRX | VERA |
|---|---|---|
| Beta | 2.88 | 1.13 |
| Sharpe ratio | -0.26 | 0.72 |
| Sortino ratio | -0.5 | 1.43 |
| Max drawdown | -58.2% | -48.1% |
| Current drawdown | -53.5% | -39.6% |
| Annualized volatility | 71.8% | 59.4% |
| Value at risk (95%) | -6.6% | -4.5% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, RXRX or VERA?
On the Algovestiq AIQ Score, VERA is the stronger of the two as of Sep 11, 2026, scoring 41 against RXRX's 37. The edge comes from momentum. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is RXRX or VERA the better buy right now?
VERA carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 4 points. Treat the lead as provisional.
Why does the AIQ Score favor VERA over RXRX?
The composite weights Quality, Value, Momentum and Risk Resilience. VERA leads Momentum by 11 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, RXRX or VERA?
Analyst price targets imply +68.8% upside for RXRX and +147.5% for VERA, so the Street currently favors VERA. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, RXRX or VERA?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, RXRX or VERA?
VERA on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, RXRX or VERA?
VERA on the Momentum factor, by 11 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, RXRX or VERA?
VERA is the more resilient of the two, so the other name carries the higher downside risk. VERA carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is RXRX more profitable than VERA?
RXRX leads on the comparable margin measures — gross margin -46.7% vs 0%; operating margin -9.9% vs 0%; ttm roe -50.4% vs -84.1%.
Is VERA's lead over RXRX getting stronger or weaker?
VERA lead: Reversed — RXRX led by 7 AIQ points 30 sessions ago; VERA now leads by 4. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 7 times in that window, most recently on 2026-09-09, when VERA moved ahead of RXRX.
What would change the RXRX vs VERA verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: RXRX closes the Momentum gap — currently 11 points behind, the largest single contributor to VERA's edge; RXRX's Death Cross Active resolves — a bearish trend rule currently active against it; VERA's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about RXRX and VERA?
RXRX: 0 bullish / 3 bearish / 1 neutral. VERA: 1 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on RXRX is Death Cross Active (bearish, long horizon). On VERA it is Death Cross Active (bearish, long horizon).
Compare RXRX and VERA with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.